November 9-12, 2021
Boston Park Plaza - 50 Park Plaza At Arlington - Boston, MA 02116


Featured IMPACT-AD Faculty and Trainees:

On-site Program:

Date & Time
IMPACT-AD Presenters
November 9 @ 4 pm ET
Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer’s Disease Therapeutic Research Presented to Ronald C. Petersen, MD, PhD, in recognition for his extensive contributions to the science and therapeutics of Alzheimer’s Disease
Paul Aisen - Faculty
November 9 @ 4:15 pm ET
KEYNOTE 1 Therapeutic Trials in Alzheimer’s Disease: A New Hope for 2022?
Ronald C. Petersen - Faculty
November 9 @ 4:35 pm ET
ROUNDTABLE 1 The FDA accelerated approval of aducanumab: a panel discussion
Paul Aisen, Maria Carrillo, Jason Karlawish - Faculty
November 10 @ 9:35 am ET
OC4- Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): Methodology for a Randomized, DoubleBlind, Placebo-Controlled Phase II Trial
Miranda E. Orr - Class of 2020
November 10 @ 2 pm ET
LATE-BREAKING READOUT ROUNDTABLE 5 Assessment of the Clinical Effects of Lecanemab, the Correlation of Plasma Aβ 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer’s Disease
Jeffrey Cummings - Faculty
November 10 @ 3:15 pm ET
OC11 - Impact of Cocoa Flavanols and Multivitamins on Cognitive Function: Findings COSMOS-MIND
Laura Baker - Faculty
November 11 @ 8.20 a.m ET
OC13 - Targeted medication therapy management can successfully augment cognitive reserve in predementia Alzheimer’s disease: Results from the INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE) Study
Gregory Jicha - Faculty
November 11 @ 9:35 am ET
LB4 - Introduction of plasma biomarker screening for the AHEAD 3-45 Study
Reisa Sperling - Faculty
November 11 @ 10:20 am ET
LB5 - Efforts to improve recruitment and engagement of underrepresented populations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study
Miriam T. Ashford - Class of 2021
November 11 @ 2:20 pm ET
KEYNOTE 4 Biostatistics in Alzheimer’s Disease Therapeutic Trials: A Future of Convergence Introduction
Rema Raman - Course Co-Director
November 11 @ 4:10 pm ET
ROUNDTABLE 7 Value-Generating Exploratory Trials in Neurodegenerative Dementias
Jeffrey Cummings - Faculty
November 12 @ 2:35 pm ET
OC35 - The Internet-based conversational engagement clinical trial (I-CONECT) in socially isolated adults 75+ years old: Randomized controlled trial protocol and COVID-19 related study modifications
Hiroko H. Dodge - Faculty
November 12 @ 3:20 pm ET
Statistics workshop: re-thinking trial outcomes
Paul Aisen - Faculty

In-Person Posters:

IMPACT-AD Presenters
Clinical trials: methodology
P31 ECT-AD Trial: Challenges to Startup & Recruitment
Maria Lapid - Class of 2021
Clinical trials: methodology
P35 - Effects of inclusion/exclusion criteria on ethnocultural and socioeconomic composition of participants in an Alzheimer’s disease clinical trial: Analysis of Health and Retirement Study (HRS) data
Miriam T. Ashford - Class of 2021
Cognitive assessment and clinical trials
P59 - Use of app-based cognitive assessments during the COVID-19 pandemic: adherence and acceptability among cognitively normal older adults
Louisa Thompson - Class of 2020

Online Program:

IMPACT-AD Presenters
Tuesday, November 9th
LBR3 - National Alzheimer’s Disease Clinical Trial Sites’ Accommodations to the COVID-19 Pandemic
Elizabeth Rhodus - Class of 2020
Wednesday, November 10th
RS4 - Innovative Approaches and Technologies Shaping the Future of Alzheimer’s Clinical Trials
Jeffrey Cummings - Faculty